Elyxium Wealth LLC Has $321,000 Holdings in Pfizer Inc. (NYSE:PFE)

Elyxium Wealth LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 65.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,102 shares of the biopharmaceutical company’s stock after selling 22,468 shares during the period. Elyxium Wealth LLC’s holdings in Pfizer were worth $321,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the fourth quarter valued at about $26,000. Clarity Asset Management Inc. acquired a new stake in Pfizer during the fourth quarter worth about $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the 4th quarter valued at approximately $28,000. Finally, Noble Wealth Management PBC bought a new stake in shares of Pfizer in the 4th quarter worth approximately $31,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

NYSE PFE opened at $22.97 on Friday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $130.26 billion, a P/E ratio of 16.29, a PEG ratio of 0.64 and a beta of 0.58. The company has a 50-day moving average price of $24.08 and a 200-day moving average price of $25.61. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was down 7.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.82 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.49%. Pfizer’s payout ratio is presently 124.64%.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.06% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PFE. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, UBS Group increased their price objective on Pfizer from $24.00 to $25.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.